4.6 Article

Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort

Journal

THORAX
Volume 77, Issue 1, Pages 65-73

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2021-217080

Keywords

COVID-19; clinical epidemiology; tobacco control

Funding

  1. Cancer Research UK [DCS-CRUK-CRTF20-AC]
  2. UK Medical Research Council [MC_UU_00011/7]
  3. European Research Council [758813 MHINT]
  4. National Institute for Health Research (NIHR) Biomedical Research Centre at the University Hospitals Bristol National Health Service Foundation Trust
  5. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) Obesity, Diet and Lifestyle Theme
  6. NIHR Oxford and Thames Valley Applied Research Collaboration
  7. National Institute for Health Research Biomedical Research Centre, Oxford
  8. John Fell Oxford University Press Research Fund
  9. Cancer Research UK through the Cancer Research UK Oxford Centre [C5255/A18085]
  10. Oxford Wellcome Institutional Strategic Support Fund [204826/Z/16/Z]
  11. British Heart Foundation Fellowship [FS/14/55/30806]
  12. Oxford Biomedical Research Centre
  13. BHF Oxford Centre for Research Excellence
  14. Nuffield Department of Population Health

Ask authors/readers for more resources

Analysis of UK Biobank data reveals a significant positive association between smoking and risk of COVID-19 infection, hospitalization, and death, supporting a causal effect of smoking on severe COVID-19.
Background Conflicting evidence has emerged regarding the relevance of smoking on risk of COVID-19 and its severity. Methods We undertook large-scale observational and Mendelian randomisation (MR) analyses using UK Biobank. Most recent smoking status was determined from primary care records (70.8%) and UK Biobank questionnaire data (29.2%). COVID-19 outcomes were derived from Public Health England SARS-CoV-2 testing data, hospital admissions data, and death certificates (until 18 August 2020). Logistic regression was used to estimate associations between smoking status and confirmed SARS-CoV-2 infection, COVID-19-related hospitalisation, and COVID-19-related death. Inverse variance-weighted MR analyses using established genetic instruments for smoking initiation and smoking heaviness were undertaken (reported per SD increase). Results There were 421 469 eligible participants, 1649 confirmed infections, 968 COVID-19-related hospitalisations and 444 COVID-19-related deaths. Compared with never-smokers, current smokers had higher risks of hospitalisation (OR 1.80, 95% CI 1.26 to 2.29) and mortality (smoking 1-9/day: OR 2.14, 95% CI 0.87 to 5.24; 10-19/day: OR 5.91, 95% CI 3.66 to 9.54; 20+/day: OR 6.11, 95% CI 3.59 to 10.42). In MR analyses of 281 105 White British participants, genetically predicted propensity to initiate smoking was associated with higher risks of infection (OR 1.45, 95% CI 1.10 to 1.91) and hospitalisation (OR 1.60, 95% CI 1.13 to 2.27). Genetically predicted higher number of cigarettes smoked per day was associated with higher risks of all outcomes (infection OR 2.51, 95% CI 1.20 to 5.24; hospitalisation OR 5.08, 95% CI 2.04 to 12.66; and death OR 10.02, 95% CI 2.53 to 39.72). Interpretation Congruent results from two analytical approaches support a causal effect of smoking on risk of severe COVID-19.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available